How to buy Applied Therapeutics stock

Applied Therapeutics, Inc is a biotechnology business based in the US. Applied Therapeutics shares (APLT) are listed on the NASDAQ and all prices are listed in US Dollars. Applied Therapeutics employs 24 staff and has a market cap (total outstanding shares value) of 0.00.

Applied Therapeutics share price

Use our graph to track the performance of APLT stocks over time.

Applied Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$13.58 - $51.99
50-day moving average	$18.14
200-day moving average	$20.57
Wall St. target price	$49.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.69

Buy Applied Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Applied Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Applied Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Applied Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-77.23%
Return on equity TTM	-164.06%
Profit margin	0%
Book value	$3.64
Market capitalisation	$472.9 million

TTM: trailing 12 months

Shorting Applied Therapeutics shares

There are currently 1.5 million Applied Therapeutics shares held short by investors – that's known as Applied Therapeutics's "short interest". This figure is 4.9% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Applied Therapeutics shares can be evaluated.

Applied Therapeutics's "short interest ratio" (SIR)

Applied Therapeutics's "short interest ratio" (SIR) is the quantity of Applied Therapeutics shares currently shorted divided by the average quantity of Applied Therapeutics shares traded daily (recently around 99452.281616688). Applied Therapeutics's SIR currently stands at 15.34. In other words for every 100,000 Applied Therapeutics shares traded daily on the market, roughly 15340 shares are currently held short.

However Applied Therapeutics's short interest can also be evaluated against the total number of Applied Therapeutics shares, or, against the total number of tradable Applied Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Applied Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Applied Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0869% of the tradable shares (for every 100,000 tradable Applied Therapeutics shares, roughly 87 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Applied Therapeutics.

Find out more about how you can short Applied Therapeutics stock.

Applied Therapeutics share dividends

We're not expecting Applied Therapeutics to pay a dividend over the next 12 months.

Applied Therapeutics overview

Applied Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Frequently asked questions

• What percentage of Applied Therapeutics is owned by insiders or institutions?

  Currently 19.905% of Applied Therapeutics shares are held by insiders and 61.88% by institutions.

• How many people work for Applied Therapeutics?

  Latest data suggests 24 work at Applied Therapeutics.

• When does the fiscal year end for Applied Therapeutics?

  Applied Therapeutics's fiscal year ends in December.

• Where is Applied Therapeutics based?

  Applied Therapeutics's address is: 545 Fifth Avenue, New York, NY, United States, 10017

• What is Applied Therapeutics's ISIN number?

  Applied Therapeutics's international securities identification number is: US03828A1016

• What is Applied Therapeutics's CUSIP number?

  Applied Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03828A101